The involvement of HIF-1α-dependent paracrine factors in Alzheimer's disease

Victoria I Zhdankina1, Elizaveta S Perepelitsa1, Anna V Blagova1

  • 1Russian Center of Neurology and Neurosciences, 80, Volokolamskoye Highway, 125367, Moscow, Russia.

PubMed

Activated HIF-1α is a key regulator of various paracrine factors that influence vascular tone, angiogenesis, and cell survival, including endothelin-1, VEGF, Ang-2, erythropoietin, and SDF-1/CXCL12. These factors not only play established roles in vascular biology but are also critical in modulating neurogenesis. The intricate relationship between the brain's vascular system and its neurogenic niches underscores the importance of HIF-1 in facilitating their interactions. Angiogenesis and proper vessel perfusion are vital for the maintenance and proliferation of neural progenitor cells, especially in the context of neurodegenerative diseases such as Alzheimer's disease (AD). In AD, impaired angiogenesis can negatively impact neurogenesis, exacerbating cognitive decline. Recent transcriptomic and proteomic studies have revealed significant upregulation of HIF-1α expression in AD patients, indicating its potential involvement in the pathophysiology of this disease. This review aims to elucidate the role of HIF-1α and related hypoxia-inducible factors in AD, focusing on their diagnostic and therapeutic implications. We specifically examine two critical neurogenic niches in the adult brain: the subventricular zone (SVZ) and the subgranular zone (SGZ). Understanding how HIF-1α affects neurogenesis in these regions may offer novel insights into potential therapeutic strategies for AD, highlighting the need for further research into the intersection of hypoxia, angiogenesis, and neurogenesis in the context of neurodegeneration. By exploring these connections, we hope to contribute to a better understanding of AD pathophysiology and identify new avenues for intervention.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.6K